Eplerenone

Generic Name: Eplerenone

Brand Names: Inspra

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₆

CAS Number: 107724-20-9

Unique Ingredient Identifier: 6995V82D0B

Background: Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication: For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions: Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)

Associated Therapies: -

Clinical Trials

Pressure Assessment to Improve Outcomes After TAVR: a Registry

Early Phase 1

Completed

Conditions: Quality of Life
Heart Failure With Preserved Ejection Fraction
Hypertension
Aortic Stenosis, Calcific

Interventions: Drug: Eplerenone

First Posted Date: 2019-04-22

Last Posted Date: 2020-05-28

Lead Sponsor: North Florida Foundation for Research and Education

Target Recruit Count: 12

Registration Number: NCT03923530

Locations: 🇺🇸
Malcom Randall VA Medical Center, Gainesville, Florida, United States

Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: Eplerenone

First Posted Date: 2017-11-17

Last Posted Date: 2023-07-11

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 1165

Registration Number: NCT03342690

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BI 690517
Drug: Eplerenone
Drug: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2020-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT03165240

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
🇩🇰
Bispebjerg og Frederiksberg Hospital, København NV, Denmark
🇩🇰
Copenhagen University Hospital, Rigshospitalet, København Ø, Denmark

and more 37 locations

Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy

Phase 4

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Other: Photodynamic therapy
Drug: Eplerenone

First Posted Date: 2017-03-14

Last Posted Date: 2019-10-23

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 107

Registration Number: NCT03079141

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands